COVID-19 due to the B.1.617.2 (Delta) variant compared to B.1.1.7 (Alpha) variant of SARS-CoV-2: a prospective observational cohort study

Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study

(2021) Cristina Menni et al.   LANCET INFECTIOUS DISEASES

Symptoms and syndromes associated with SARS-CoV-2 infection and severity in pregnant women from two community cohorts

(2021) Erika Molteni et al.   Scientific Reports

Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study

(2021) Mark S Graham et al.   Lancet Public Health

The substitution spectra of coronavirus genomes

(2021) Diego Forni et al.   BRIEFINGS IN BIOINFORMATICS

Clinical and virological features of SARS-CoV-2 variants of concern: a retrospective cohort study comparing B.1.1.7 (Alpha), B.1.315 (Beta), and B.1.617.2 (Delta)

(2021) Sean Wei Xiang Ong et al.   CLINICAL INFECTIOUS DISEASES

Seroprevalence of SARS-CoV-2 antibodies and reduced risk of reinfection through six months: a Danish observational cohort study of 44,000 healthcare workers

(2021) Kasper Iversen et al.   CLINICAL MICROBIOLOGY AND INFECTION

SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness

(2021) Aziz Sheikh et al.   LANCET

Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study

(2021) Michela Antonelli et al.   LANCET INFECTIOUS DISEASES

Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study

(2021) Katherine A Twohig et al.   LANCET INFECTIOUS DISEASES

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

(2021) Delphine Planas et al.   NATURE

Author Correction: Attributes and predictors of long COVID

(2021) Carole H. Sudre et al.   NATURE MEDICINE

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

(2021) Jamie Lopez Bernal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Outbreak Associated with SARS-CoV-2 B.1.617.2 (Delta) Variant in an Elementary School — Marin County, California, May–June 2021

(2021) Tracy Lam-Hine et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

Protective Immunity after Natural Infection with Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) – Kentucky, USA, 2020

(2021) Kevin B. Spicer et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity

(2021) Mark W. Tenforde et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Genomic reconstruction of the SARS-CoV-2 epidemic in England

(2021) Harald S. Vöhringer et al.   NATURE

Waning Immunity after the BNT162b2 Vaccine in Israel

(2021) Yair Goldberg et al.   NEW ENGLAND JOURNAL OF MEDICINE

Accessible data curation and analytics for international-scale citizen science datasets

(2021) Benjamin Murray et al.   Scientific Data

Real-time tracking of self-reported symptoms to predict potential COVID-19

(2020) Cristina Menni et al.   NATURE MEDICINE

Rapid implementation of mobile technology for real-time epidemiology of COVID-19

(2020) David A. Drew et al.   SCIENCE

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

(2020) Maheshi N Ramasamy et al.   LANCET

Antigenic variation of SARS‐CoV‐2 in response to immune pressure

(2020) Diego Forni et al.   MOLECULAR ECOLOGY

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

(2020) Fernando P. Polack et al.   NEW ENGLAND JOURNAL OF MEDICINE

Detecting COVID-19 infection hotspots in England using large-scale self-reported data from a mobile application: a prospective, observational study

(2020) Thomas Varsavsky et al.   Lancet Public Health